MetaCap

IRulya Therapeutics Cash Flow Statement

NASDAQ: IRLAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

39.88-0.06 (-0.15%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

IRulya Therapeutics free cash flow

In fiscal 2025, IRulya Therapeutics generated -$41.4 million of operating cash flow and spent $352,000 on capital expenditures. That left free cash flow of -$41.8 million.

Summary generated from market data by MetaCap's automated system. Methodology

IRulya Therapeutics cash flow statement (annual)

IRulya Therapeutics annual cash flow statement
Fiscal year (USD)FY 20252025-12-31FY 20242024-12-31FY 20232023-12-31FY 20222022-12-31FY 20212021-12-31FY 20202020-12-31FY 20192019-12-31FY 20182018-12-31
Net Income-83.98M-56.83M-31.39M-51.66M-89.94M-76.85M-36.98M-12.48M
Net Income growth (YoY)————————
Depreciation & Amortization142.00K186.00K322.00K204.00K344.00K332.00K188.00K51.00K
Stock-Based Compensation5.11M4.75M5.22M16.62M29.85M14.47M2.06M155.00K
Change in Working Capital2.76M-675.00K3.96M-3.36M527.00K2.66M-2.74M-713.00K
Operating Cash Flow-41.42M-31.90M-18.29M-44.04M-62.93M-50.82M-33.28M-11.70M
Capital Expenditures-352.00K-257.00K-160.00K-133.00K-180.00K-52.00K-55.00K-212.00K
Investing Cash Flow23.23M21.91M-5.76M18.00M58.95M-52.43M-17.75M-46.75M
Financing Cash Flow17.91M-4.78M143.00K707.00K6.81M118.88M77.37M75.93M
Net Change in Cash-403.00K-14.54M-23.83M-25.14M2.88M15.63M26.34M17.48M
Free Cash Flow-41.78M-32.16M-18.45M-44.17M-63.11M-50.87M-33.33M-11.91M

This table shows 8 annual periods of IRulya Therapeutics's cash flow statement, from FY 2025 back to FY 2018, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow IRLA's reporting calendar. What is a cash flow statement?

More financial data